Literature DB >> 33330768

Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up.

Shinichi Oka1, Kazuko Ikeda1, Misao Takano1, Miwa Ogane1, Junko Tanuma1, Kunihisa Tsukada1, Hiroyuki Gatanaga1.   

Abstract

Nearly 30% of Japanese hemophiliacs were infected with HIV-1 in the early 1980s. They have unique characteristics compared to HIV-1-infected individuals through other routes, including date of infection of 1986 or earlier, mean age of nearly 50 years, and common co-infection with hepatitis C, but rarely with other sexually transmitted diseases. Antiretroviral therapy (ART) was introduced in Japan in 1997. The clinical courses before and after 1997 were quite different. Careful analysis of the pre-1997 clinical data allowed expansion of our knowledge about the natural course and pathogenesis of the disease. Switching to the second receptor agents proved critical in subsequent disease progression. HIV-1 continued to escape immune pressure, pushing disease progression faster. In contrast, ART was effective enough to overcome the natural course. Prognosis improved dramatically and cause of death changed from AIDS-related opportunistic infections and malignancies before 1997, to hepatitis C virus-related cirrhosis and hepatocellular carcinoma (HCC) around 2010, and again to non-AIDS defining malignancies recently. In most cases, hepatitis C was cured with direct acting antiviral therapy. However, HCV progressed to cirrhosis in some cases and risk of HCC is still high among these patients. Together with improvement in anticoagulants and aging of the patients, risk of myocardial infarction has increased recently. In addition, the numbers of patients with life-style related co-morbidities, such as diabetes mellitus, hypertension, and chronic kidney disease have been also increasing. Finally, stigma is still an important barrier to a better life in HIV-1-positive individuals. 2020, National Center for Global Health and Medicine.

Entities:  

Keywords:  HCV co-infection; antiretroviral therapy; cause of death; co-morbidity; escape from immune pressure; natural course

Year:  2020        PMID: 33330768      PMCID: PMC7731362          DOI: 10.35772/ghm.2019.01030

Source DB:  PubMed          Journal:  Glob Health Med        ISSN: 2434-9186


  57 in total

1.  Current characteristics of hemophilia patients co-infected with HIV/HCV in Japan.

Authors:  Satoshi Miuma; Masaaki Hidaka; Mitsuhisa Takatsuki; Koji Natsuda; Akihiko Soyama; Hisamitsu Miyaaki; Yasuko Kanda; Yoko Tamada; Hidetaka Shibata; Eisuke Ozawa; Naota Taura; Susumu Eguchi; Kazuhiko Nakao
Journal:  Exp Ther Med       Date:  2017-12-07       Impact factor: 2.447

2.  The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

Authors:  Y Huang; W A Paxton; S M Wolinsky; A U Neumann; L Zhang; T He; S Kang; D Ceradini; Z Jin; K Yazdanbakhsh; K Kunstman; D Erickson; E Dragon; N R Landau; J Phair; D D Ho; R A Koup
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

3.  Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1981-07-03       Impact factor: 17.586

4.  1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.

Authors:  M M Mansuri; J E Starrett; I Ghazzouli; M J Hitchcock; R Z Sterzycki; V Brankovan; T S Lin; E M August; W H Prusoff; J P Sommadossi
Journal:  J Med Chem       Date:  1989-02       Impact factor: 7.446

5.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

6.  Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: experience in a single center.

Authors:  Kunihisa Tsukada; Yasuhiko Sugawara; Junichi Kaneko; Sumihito Tamura; Natsuo Tachikawa; Yuji Morisawa; Shu Okugawa; Yoshimi Kikuchi; Shinichi Oka; Satoshi Kimura; Yutaka Yatomi; Masatoshi Makuuchi; Norihiro Kokudo; Kazuhiko Koike
Journal:  Transplantation       Date:  2011-06-15       Impact factor: 4.939

7.  An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction.

Authors:  H Masur; M A Michelis; J B Greene; I Onorato; R A Stouwe; R S Holzman; G Wormser; L Brettman; M Lange; H W Murray; S Cunningham-Rundles
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

8.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors:  A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245

10.  Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.

Authors:  Margaret T May; Mark Gompels; Valerie Delpech; Kholoud Porter; Chloe Orkin; Stephen Kegg; Phillip Hay; Margaret Johnson; Adrian Palfreeman; Richard Gilson; David Chadwick; Fabiola Martin; Teresa Hill; John Walsh; Frank Post; Martin Fisher; Jonathan Ainsworth; Sophie Jose; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

View more
  2 in total

Review 1.  AIDS at 40th: The progress of HIV treatment in Japan.

Authors:  Shinichi Oka
Journal:  Glob Health Med       Date:  2022-02-28

2.  Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan.

Authors:  Daniel J Ruzicka; Mayuko Kamakura; Naho Kuroishi; Nobuyuki Oshima; Miyuki Yamatani; Jingbo Yi; Bruce Crawford; Kunihisa Tsukada; Shinichi Oka
Journal:  PLoS One       Date:  2022-06-14       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.